Market Intelligence chevron_right Medical Care chevron_right Selective Cox-2 Inhibitors
Global Report 2021

Global Selective Cox-2 Inhibitors Market Size, Status and Forecast 2024-2031

calendar_todayPublished: Dec 2021 descriptionPages: 128 categoryCategory: Medical Care
cloud_downloadRequest Sample Report
mailPre-Order Enquiry
local_offerGet Discount 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Meloxicam
        1.2.3 Celecoxib
        1.2.4 Etoricoxib
        1.2.5 Imrecoxib
        1.2.6 Etodolac
        1.2.7 Parecoxib
        1.2.8 Other
    1.3 Market by Application
        1.3.1 Global Selective Cox-2 Inhibitors Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Rheumatoid Arthritis
        1.3.3 Osteoarthritis
        1.3.4 Spondylosis Chronica Ankylopoietica
        1.3.5 Other
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Selective Cox-2 Inhibitors Market Perspective (2016-2027)
    2.2 Selective Cox-2 Inhibitors Growth Trends by Regions
        2.2.1 Selective Cox-2 Inhibitors Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Selective Cox-2 Inhibitors Historic Market Share by Regions (2016-2021)
        2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2022-2027)
    2.3 Selective Cox-2 Inhibitors Industry Dynamic
        2.3.1 Selective Cox-2 Inhibitors Market Trends
        2.3.2 Selective Cox-2 Inhibitors Market Drivers
        2.3.3 Selective Cox-2 Inhibitors Market Challenges
        2.3.4 Selective Cox-2 Inhibitors Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Selective Cox-2 Inhibitors Players by Revenue
        3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2016-2021)
        3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2016-2021)
    3.2 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
    3.4 Global Selective Cox-2 Inhibitors Market Concentration Ratio
        3.4.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2020
    3.5 Selective Cox-2 Inhibitors Key Players Head office and Area Served
    3.6 Key Players Selective Cox-2 Inhibitors Product Solution and Service
    3.7 Date of Enter into Selective Cox-2 Inhibitors Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Selective Cox-2 Inhibitors Breakdown Data by Type
    4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2016-2021)
    4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2022-2027)

5 Selective Cox-2 Inhibitors Breakdown Data by Application
    5.1 Global Selective Cox-2 Inhibitors Historic Market Size by Application (2016-2021)
    5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Selective Cox-2 Inhibitors Market Size (2016-2027)
    6.2 North America Selective Cox-2 Inhibitors Market Size by Type
        6.2.1 North America Selective Cox-2 Inhibitors Market Size by Type (2016-2021)
        6.2.2 North America Selective Cox-2 Inhibitors Market Size by Type (2022-2027)
        6.2.3 North America Selective Cox-2 Inhibitors Market Size by Type (2016-2027)
    6.3 North America Selective Cox-2 Inhibitors Market Size by Application
        6.3.1 North America Selective Cox-2 Inhibitors Market Size by Application (2016-2021)
        6.3.2 North America Selective Cox-2 Inhibitors Market Size by Application (2022-2027)
        6.3.3 North America Selective Cox-2 Inhibitors Market Size by Application (2016-2027)
    6.4 North America Selective Cox-2 Inhibitors Market Size by Country
        6.4.1 North America Selective Cox-2 Inhibitors Market Size by Country (2016-2021)
        6.4.2 North America Selective Cox-2 Inhibitors Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Selective Cox-2 Inhibitors Market Size (2016-2027)
    7.2 Europe Selective Cox-2 Inhibitors Market Size by Type
        7.2.1 Europe Selective Cox-2 Inhibitors Market Size by Type (2016-2021)
        7.2.2 Europe Selective Cox-2 Inhibitors Market Size by Type (2022-2027)
        7.2.3 Europe Selective Cox-2 Inhibitors Market Size by Type (2016-2027)
    7.3 Europe Selective Cox-2 Inhibitors Market Size by Application
        7.3.1 Europe Selective Cox-2 Inhibitors Market Size by Application (2016-2021)
        7.3.2 Europe Selective Cox-2 Inhibitors Market Size by Application (2022-2027)
        7.3.3 Europe Selective Cox-2 Inhibitors Market Size by Application (2016-2027)
    7.4 Europe Selective Cox-2 Inhibitors Market Size by Country
        7.4.1 Europe Selective Cox-2 Inhibitors Market Size by Country (2016-2021)
        7.4.2 Europe Selective Cox-2 Inhibitors Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size (2016-2027)
    8.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type
        8.2.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2016-2027)
    8.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application
        8.3.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2016-2027)
    8.4 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region
        8.4.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Selective Cox-2 Inhibitors Market Size (2016-2027)
    9.2 Latin America Selective Cox-2 Inhibitors Market Size by Type
        9.2.1 Latin America Selective Cox-2 Inhibitors Market Size by Type (2016-2021)
        9.2.2 Latin America Selective Cox-2 Inhibitors Market Size by Type (2022-2027)
        9.2.3 Latin America Selective Cox-2 Inhibitors Market Size by Type (2016-2027)
    9.3 Latin America Selective Cox-2 Inhibitors Market Size by Application
        9.3.1 Latin America Selective Cox-2 Inhibitors Market Size by Application (2016-2021)
        9.3.2 Latin America Selective Cox-2 Inhibitors Market Size by Application (2022-2027)
        9.3.3 Latin America Selective Cox-2 Inhibitors Market Size by Application (2016-2027)
    9.4 Latin America Selective Cox-2 Inhibitors Market Size by Country
        9.4.1 Latin America Selective Cox-2 Inhibitors Market Size by Country (2016-2021)
        9.4.2 Latin America Selective Cox-2 Inhibitors Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size (2016-2027)
    10.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type
        10.2.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2016-2027)
    10.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application
        10.3.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2016-2027)
    10.4 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country
        10.4.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Boehringer-Ingelheim
        11.1.1 Boehringer-Ingelheim Company Details
        11.1.2 Boehringer-Ingelheim Business Overview
        11.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
        11.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.1.5 Boehringer-Ingelheim Recent Development
    11.2 TerSera Therapeutics
        11.2.1 TerSera Therapeutics Company Details
        11.2.2 TerSera Therapeutics Business Overview
        11.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
        11.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.2.5 TerSera Therapeutics Recent Development
    11.3 Iroko Pharmaceuticals
        11.3.1 Iroko Pharmaceuticals Company Details
        11.3.2 Iroko Pharmaceuticals Business Overview
        11.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.3.5 Iroko Pharmaceuticals Recent Development
    11.4 Apotex
        11.4.1 Apotex Company Details
        11.4.2 Apotex Business Overview
        11.4.3 Apotex Selective Cox-2 Inhibitors Introduction
        11.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.4.5 Apotex Recent Development
    11.5 Yung Shin Pharmaceutical
        11.5.1 Yung Shin Pharmaceutical Company Details
        11.5.2 Yung Shin Pharmaceutical Business Overview
        11.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.5.5 Yung Shin Pharmaceutical Recent Development
    11.6 Breckenridge Pharmaceutical
        11.6.1 Breckenridge Pharmaceutical Company Details
        11.6.2 Breckenridge Pharmaceutical Business Overview
        11.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.6.5 Breckenridge Pharmaceutical Recent Development
    11.7 Meda Pharmaceuticals
        11.7.1 Meda Pharmaceuticals Company Details
        11.7.2 Meda Pharmaceuticals Business Overview
        11.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.7.5 Meda Pharmaceuticals Recent Development
    11.8 Cipla
        11.8.1 Cipla Company Details
        11.8.2 Cipla Business Overview
        11.8.3 Cipla Selective Cox-2 Inhibitors Introduction
        11.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.8.5 Cipla Recent Development
    11.9 Glenmark Pharmaceuticals
        11.9.1 Glenmark Pharmaceuticals Company Details
        11.9.2 Glenmark Pharmaceuticals Business Overview
        11.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.9.5 Glenmark Pharmaceuticals Recent Development
    11.10 Teva
        11.10.1 Teva Company Details
        11.10.2 Teva Business Overview
        11.10.3 Teva Selective Cox-2 Inhibitors Introduction
        11.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.10.5 Teva Recent Development
    11.11 PuraCap Pharmaceutical
        11.11.1 PuraCap Pharmaceutical Company Details
        11.11.2 PuraCap Pharmaceutical Business Overview
        11.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.11.5 PuraCap Pharmaceutical Recent Development
    11.12 Almirall Limited
        11.12.1 Almirall Limited Company Details
        11.12.2 Almirall Limited Business Overview
        11.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
        11.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.12.5 Almirall Limited Recent Development
    11.13 Lupin Pharmaceuticals
        11.13.1 Lupin Pharmaceuticals Company Details
        11.13.2 Lupin Pharmaceuticals Business Overview
        11.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.13.5 Lupin Pharmaceuticals Recent Development
    11.14 Aurobindo Pharma
        11.14.1 Aurobindo Pharma Company Details
        11.14.2 Aurobindo Pharma Business Overview
        11.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
        11.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.14.5 Aurobindo Pharma Recent Development
    11.15 Pfizer
        11.15.1 Pfizer Company Details
        11.15.2 Pfizer Business Overview
        11.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
        11.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.15.5 Pfizer Recent Development
    11.16 Mylan
        11.16.1 Mylan Company Details
        11.16.2 Mylan Business Overview
        11.16.3 Mylan Selective Cox-2 Inhibitors Introduction
        11.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.16.5 Mylan Recent Development
    11.17 Takeda
        11.17.1 Takeda Company Details
        11.17.2 Takeda Business Overview
        11.17.3 Takeda Selective Cox-2 Inhibitors Introduction
        11.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.17.5 Takeda Recent Development
    11.18 Bayer
        11.18.1 Bayer Company Details
        11.18.2 Bayer Business Overview
        11.18.3 Bayer Selective Cox-2 Inhibitors Introduction
        11.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.18.5 Bayer Recent Development
    11.18 Novacap
        11.25.1 Novacap Company Details
        11.25.2 Novacap Business Overview
        11.25.3 Novacap Selective Cox-2 Inhibitors Introduction
        11.25.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.25.5 Novacap Recent Development
    11.20 Abbott
        11.20.1 Abbott Company Details
        11.20.2 Abbott Business Overview
        11.20.3 Abbott Selective Cox-2 Inhibitors Introduction
        11.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.20.5 Abbott Recent Development
    11.21 Geri-Care
        11.21.1 Geri-Care Company Details
        11.21.2 Geri-Care Business Overview
        11.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
        11.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.21.5 Geri-Care Recent Development
    11.22 Perrigo
        11.22.1 Perrigo Company Details
        11.22.2 Perrigo Business Overview
        11.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
        11.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.22.5 Perrigo Recent Development
    11.23 Kopran
        11.23.1 Kopran Company Details
        11.23.2 Kopran Business Overview
        11.23.3 Kopran Selective Cox-2 Inhibitors Introduction
        11.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.23.5 Kopran Recent Development
    11.24 Merck
        11.24.1 Merck Company Details
        11.24.2 Merck Business Overview
        11.24.3 Merck Selective Cox-2 Inhibitors Introduction
        11.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.24.5 Merck Recent Development
    11.25 Hengrui pharmaceutical
        11.25.1 Hengrui pharmaceutical Company Details
        11.25.2 Hengrui pharmaceutical Business Overview
        11.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.25.5 Hengrui pharmaceutical Recent Development
    11.26 Kelun Group
        11.26.1 Kelun Group Company Details
        11.26.2 Kelun Group Business Overview
        11.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
        11.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.26.5 Kelun Group Recent Development
    11.27 Qilu Pharmaceutical
        11.27.1 Qilu Pharmaceutical Company Details
        11.27.2 Qilu Pharmaceutical Business Overview
        11.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.27.5 Qilu Pharmaceutical Recent Development
    11.28 Taro Pharmaceuticals 
        11.28.1 Taro Pharmaceuticals  Company Details
        11.28.2 Taro Pharmaceuticals  Business Overview
        11.28.3 Taro Pharmaceuticals  Selective Cox-2 Inhibitors Introduction
        11.28.4 Taro Pharmaceuticals  Revenue in Selective Cox-2 Inhibitors Business (2016-2021)
        11.28.5 Taro Pharmaceuticals  Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Meloxicam
    Table 3. Key Players of Celecoxib
    Table 4. Key Players of Etoricoxib
    Table 5. Key Players of Imrecoxib
    Table 6. Key Players of Etodolac
    Table 7. Key Players of Parecoxib
    Table 8. Key Players of Other
    Table 9. Global Selective Cox-2 Inhibitors Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 10. Global Selective Cox-2 Inhibitors Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 11. Global Selective Cox-2 Inhibitors Market Size by Regions (2016-2021) & (US$ Million)
    Table 12. Global Selective Cox-2 Inhibitors Market Share by Regions (2016-2021)
    Table 13. Global Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 14. Global Selective Cox-2 Inhibitors Market Share by Regions (2022-2027)
    Table 15. Selective Cox-2 Inhibitors Market Trends
    Table 16. Selective Cox-2 Inhibitors Market Drivers
    Table 17. Selective Cox-2 Inhibitors Market Challenges
    Table 18. Selective Cox-2 Inhibitors Market Restraints
    Table 19. Global Selective Cox-2 Inhibitors Revenue by Players (2016-2021) & (US$ Million)
    Table 20. Global Selective Cox-2 Inhibitors Market Share by Players (2016-2021)
    Table 21. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Cox-2 Inhibitors as of 2020)
    Table 22. Ranking of Global Top Selective Cox-2 Inhibitors Companies by Revenue (US$ Million) in 2020
    Table 23. Global 5 Largest Players Market Share by Selective Cox-2 Inhibitors Revenue (CR5 and HHI) & (2016-2021)
    Table 24. Key Players Headquarters and Area Served
    Table 25. Key Players Selective Cox-2 Inhibitors Product Solution and Service
    Table 26. Date of Enter into Selective Cox-2 Inhibitors Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Selective Cox-2 Inhibitors Market Size by Type (2016-2021) (US$ Million)
    Table 29. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2016-2021)
    Table 30. Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 31. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 32. Global Selective Cox-2 Inhibitors Market Size Share by Application (2016-2021) & (US$ Million)
    Table 33. Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2016-2021)
    Table 34. Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 35. Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 36. North America Selective Cox-2 Inhibitors Market Size by Type (2016-2021) (US$ Million)
    Table 37. North America Selective Cox-2 Inhibitors Market Size by Type (2022-2027) & (US$ Million)
    Table 38. North America Selective Cox-2 Inhibitors Market Size by Application (2016-2021) (US$ Million)
    Table 39. North America Selective Cox-2 Inhibitors Market Size by Application (2022-2027) & (US$ Million)
    Table 40. North America Selective Cox-2 Inhibitors Market Size by Country (2016-2021) & (US$ Million) 
    Table 41. North America Selective Cox-2 Inhibitors Market Size by Country (2022-2027) & (US$ Million) 
    Table 42. Europe Selective Cox-2 Inhibitors Market Size by Type (2016-2021) (US$ Million)
    Table 43. Europe Selective Cox-2 Inhibitors Market Size by Type (2022-2027) & (US$ Million)
    Table 44. Europe Selective Cox-2 Inhibitors Market Size by Application (2016-2021) (US$ Million)
    Table 45. Europe Selective Cox-2 Inhibitors Market Size by Application (2022-2027) & (US$ Million)
    Table 46. Europe Selective Cox-2 Inhibitors Market Size by Country (2016-2021) & (US$ Million) 
    Table 47. Europe Selective Cox-2 Inhibitors Market Size by Country (2022-2027) & (US$ Million) 
    Table 48. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2016-2021) (US$ Million)
    Table 49. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2022-2027) & (US$ Million)
    Table 50. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2016-2021) (US$ Million)
    Table 51. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2022-2027) & (US$ Million)
    Table 52. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2016-2021) & (US$ Million) 
    Table 53. Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2022-2027) & (US$ Million) 
    Table 54. Latin America Selective Cox-2 Inhibitors Market Size by Type (2016-2021) (US$ Million)
    Table 55. Latin America Selective Cox-2 Inhibitors Market Size by Type (2022-2027) & (US$ Million)
    Table 56. Latin America Selective Cox-2 Inhibitors Market Size by Application (2016-2021) (US$ Million)
    Table 57. Latin America Selective Cox-2 Inhibitors Market Size by Application (2022-2027) & (US$ Million)
    Table 58. Latin America Selective Cox-2 Inhibitors Market Size by Country (2016-2021) & (US$ Million) 
    Table 59. Latin America Selective Cox-2 Inhibitors Market Size by Country (2022-2027) & (US$ Million) 
    Table 60. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2016-2021) (US$ Million)
    Table 61. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2022-2027) & (US$ Million)
    Table 62. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2016-2021) (US$ Million)
    Table 63. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2022-2027) & (US$ Million)
    Table 64. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2016-2021) & (US$ Million) 
    Table 65. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2022-2027) & (US$ Million) 
    Table 66. Boehringer-Ingelheim Company Details
    Table 67. Boehringer-Ingelheim Business Overview
    Table 68. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product
    Table 69. Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 70. Boehringer-Ingelheim Recent Development
    Table 71. TerSera Therapeutics Company Details
    Table 72. TerSera Therapeutics Business Overview
    Table 73. TerSera Therapeutics Selective Cox-2 Inhibitors Product
    Table 74. TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 75. TerSera Therapeutics Recent Development
    Table 76. Iroko Pharmaceuticals Company Details
    Table 77. Iroko Pharmaceuticals Business Overview
    Table 78. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 79. Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 80. Iroko Pharmaceuticals Recent Development
    Table 81. Apotex Company Details
    Table 82. Apotex Business Overview
    Table 83. Apotex Selective Cox-2 Inhibitors Product
    Table 84. Apotex Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 85. Apotex Recent Development
    Table 86. Yung Shin Pharmaceutical Company Details
    Table 87. Yung Shin Pharmaceutical Business Overview
    Table 88. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 89. Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 90. Yung Shin Pharmaceutical Recent Development
    Table 91. Breckenridge Pharmaceutical Company Details
    Table 92. Breckenridge Pharmaceutical Business Overview
    Table 93. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 94. Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 95. Breckenridge Pharmaceutical Recent Development
    Table 96. Meda Pharmaceuticals Company Details
    Table 97. Meda Pharmaceuticals Business Overview
    Table 98. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 99. Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 100. Meda Pharmaceuticals Recent Development
    Table 101. Cipla Company Details
    Table 102. Cipla Business Overview
    Table 103. Cipla Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 104. Cipla Recent Development
    Table 105. Glenmark Pharmaceuticals Company Details
    Table 106. Glenmark Pharmaceuticals Business Overview
    Table 107. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 108. Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 109. Glenmark Pharmaceuticals Recent Development
    Table 110. Teva Company Details
    Table 111. Teva Business Overview
    Table 112. Teva Selective Cox-2 Inhibitors Product
    Table 113. Teva Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 114. Teva Recent Development
    Table 115. PuraCap Pharmaceutical Company Details
    Table 116. PuraCap Pharmaceutical Business Overview
    Table 117. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 118. PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 119. PuraCap Pharmaceutical Recent Development
    Table 120. Almirall Limited Company Details
    Table 121. Almirall Limited Business Overview
    Table 122. Almirall Limited Selective Cox-2 Inhibitors Product
    Table 123. Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 124. Almirall Limited Recent Development
    Table 125. Lupin Pharmaceuticals Company Details
    Table 126. Lupin Pharmaceuticals Business Overview
    Table 127. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product
    Table 128. Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 129. Lupin Pharmaceuticals Recent Development
    Table 130. Aurobindo Pharma Company Details
    Table 131. Aurobindo Pharma Business Overview
    Table 132. Aurobindo Pharma Selective Cox-2 Inhibitors Product
    Table 133. Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 134. Aurobindo Pharma Recent Development
    Table 135. Pfizer Company Details
    Table 136. Pfizer Business Overview
    Table 137. Pfizer Selective Cox-2 Inhibitors Product
    Table 138. Pfizer Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 139. Pfizer Recent Development
    Table 140. Mylan Company Details
    Table 141. Mylan Business Overview
    Table 142. Mylan Selective Cox-2 Inhibitors Product
    Table 143. Mylan Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 144. Mylan Recent Development
    Table 145. Takeda Company Details
    Table 146. Takeda Business Overview
    Table 147. Takeda Selective Cox-2 Inhibitors Product
    Table 148. Takeda Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 149. Takeda Recent Development
    Table 150. Bayer Company Details
    Table 151. Bayer Business Overview
    Table 152. Bayer Selective Cox-2 Inhibitors Product
    Table 153. Bayer Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 154. Bayer Recent Development
    Table 155. Novacap Company Details
    Table 156. Novacap Business Overview
    Table 157. Novacap Selective Cox-2 Inhibitors Product
    Table 158. Novacap Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 159. Novacap Recent Development
    Table 160. Abbott Company Details
    Table 161. Abbott Business Overview
    Table 162. Abbott Selective Cox-2 Inhibitors Product
    Table 163. Abbott Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 164. Abbott Recent Development
    Table 165. Geri-Care Company Details
    Table 166. Geri-Care Business Overview
    Table 167. Geri-Care Selective Cox-2 Inhibitors Product
    Table 168. Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 169. Geri-Care Recent Development
    Table 170. Perrigo Company Details
    Table 171. Perrigo Business Overview
    Table 172. Perrigo Selective Cox-2 Inhibitors Product
    Table 173. Perrigo Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 174. Perrigo Recent Development
    Table 175. Kopran Company Details
    Table 176. Kopran Business Overview
    Table 177. Kopran Selective Cox-2 Inhibitors Product
    Table 178. Kopran Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 179. Kopran Recent Development
    Table 180. Merck Company Details
    Table 181. Merck Business Overview
    Table 182. Merck Selective Cox-2 InhibitorsProduct
    Table 183. Merck Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 184. Merck Recent Development
    Table 185. Hengrui pharmaceutical Company Details
    Table 186. Hengrui pharmaceutical Business Overview
    Table 187. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product
    Table 188. Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 189. Hengrui pharmaceutical Recent Development
    Table 190. Kelun Group Company Details
    Table 191. Kelun Group Business Overview
    Table 192. Kelun Group Selective Cox-2 Inhibitors Product
    Table 193. Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 194. Kelun Group Recent Development
    Table 195. Qilu Pharmaceutical Company Details
    Table 196. Qilu Pharmaceutical Business Overview
    Table 197. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product
    Table 198. Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 199. Qilu Pharmaceutical Recent Development
    Table 200. Taro Pharmaceuticals  Company Details
    Table 201. Taro Pharmaceuticals  Business Overview
    Table 202. Taro Pharmaceuticals  Selective Cox-2 Inhibitors Product
    Table 203. Taro Pharmaceuticals  Revenue in Selective Cox-2 Inhibitors Business (2016-2021) & (US$ Million)
    Table 204. Taro Pharmaceuticals  Recent Development
    Table 205. Research Programs/Design for This Report
    Table 206. Key Data Information from Secondary Sources
    Table 207. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Selective Cox-2 Inhibitors Market Share by Type: 2020 VS 2027
    Figure 2. Meloxicam Features
    Figure 3. Celecoxib Features
    Figure 4. Etoricoxib Features
    Figure 5. Imrecoxib Features
    Figure 6. Etodolac Features
    Figure 7. Parecoxib Features
    Figure 8. Other Features
    Figure 9. Global Selective Cox-2 Inhibitors Market Share by Application: 2020 VS 2027
    Figure 10. Rheumatoid Arthritis Case Studies
    Figure 11. Osteoarthritis Case Studies
    Figure 12. Spondylosis Chronica Ankylopoietica Case Studies
    Figure 13. Other Case Studies
    Figure 14. Selective Cox-2 Inhibitors Report Years Considered
    Figure 15. Global Selective Cox-2 Inhibitors Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 16. Global Selective Cox-2 Inhibitors Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 17. Global Selective Cox-2 Inhibitors Market Share by Regions: 2020 VS 2027
    Figure 18. Global Selective Cox-2 Inhibitors Market Share by Regions (2022-2027)
    Figure 19. Global Selective Cox-2 Inhibitors Market Share by Players in 2020
    Figure 20. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Cox-2 Inhibitors as of 2020
    Figure 21. The Top 10 and 5 Players Market Share by Selective Cox-2 Inhibitors Revenue in 2020
    Figure 22. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2016-2021)
    Figure 23. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2022-2027)
    Figure 24. North America Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. North America Selective Cox-2 Inhibitors Market Share by Type (2016-2027)
    Figure 26. North America Selective Cox-2 Inhibitors Market Share by Application (2016-2027)
    Figure 27. North America Selective Cox-2 Inhibitors Market Share by Country (2016-2027)
    Figure 28. United States Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. Canada Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. Europe Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Europe Selective Cox-2 Inhibitors Market Share by Type (2016-2027)
    Figure 32. Europe Selective Cox-2 Inhibitors Market Share by Application (2016-2027)
    Figure 33. Europe Selective Cox-2 Inhibitors Market Share by Country (2016-2027)
    Figure 34. Germany Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. France Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. U.K. Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Italy Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Russia Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Nordic Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Asia-Pacific Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Asia-Pacific Selective Cox-2 Inhibitors Market Share by Type (2016-2027)
    Figure 42. Asia-Pacific Selective Cox-2 Inhibitors Market Share by Application (2016-2027)
    Figure 43. Asia-Pacific Selective Cox-2 Inhibitors Market Share by Region (2016-2027)
    Figure 44. China Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Japan Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. South Korea Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Southeast Asia Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. India Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Australia Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Latin America Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Latin America Selective Cox-2 Inhibitors Market Share by Type (2016-2027)
    Figure 52. Latin America Selective Cox-2 Inhibitors Market Share by Application (2016-2027)
    Figure 53. Latin America Selective Cox-2 Inhibitors Market Share by Country (2016-2027)
    Figure 54. Mexico Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Brazil Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Middle East & Africa Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Middle East & Africa Selective Cox-2 Inhibitors Market Share by Type (2016-2027)
    Figure 58. Middle East & Africa Selective Cox-2 Inhibitors Market Share by Application (2016-2027)
    Figure 59. Middle East & Africa Selective Cox-2 Inhibitors Market Share by Country (2016-2027)
    Figure 60. Turkey Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 61. Saudi Arabia Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 62. UAE Selective Cox-2 Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 63. Boehringer-Ingelheim Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 64. TerSera Therapeutics Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 65. Iroko Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 66. Apotex Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 67. Yung Shin Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 68. Breckenridge Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 69. Meda Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 70. Cipla Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 71. Glenmark Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 72. Teva Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 73. PuraCap Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 74. Almirall Limited Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 75. Lupin Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 76. Aurobindo Pharma Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 77. Pfizer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 78. Mylan Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 79. Takeda Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 80. Bayer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 81. Novacap Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 82. Abbott Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 83. Geri-Care Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 84. Perrigo Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 85. Kopran Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 86. Merck Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 87. Hengrui pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 88. Kelun Group Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 89. Qilu Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 90. Taro Pharmaceuticals  Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2016-2021)
    Figure 91. Bottom-up and Top-down Approaches for This Report
    Figure 92. Data Triangulation
    Figure 93. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Takeda
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals 

Frequently Asked Questions

What is the USP of the report? expand_more
Selective Cox-2 Inhibitors report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
What are the key content of the report? expand_more
Selective Cox-2 Inhibitors report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
What are the value propositions and opportunities offered in this market research report? expand_more
Selective Cox-2 Inhibitors report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.